UPB

H.C. Wainwright initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $36.00

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET. A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio's website on the day of the event. A replay will be available on the Company's website following the presentation. About Upstream BioUpstream

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers – WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new data from the Phase 2 VIBRANT trial evaluatin

SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

10-Q - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in COPD ongoing; Company to cap further enrollment; data now expected in the second half of 2027 – – Upcoming data presentations at ATS and EAACI to further elaborate the clinical profile of verekitug – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.  (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in

DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)

Evercore ISI downgraded Upstream Bio from Outperform to In-line and set a new price target of $15.00

8-K - Upstream Bio, Inc. (0002022626) (Filer)

424B5 - Upstream Bio, Inc. (0002022626) (Filer)

S-8 - Upstream Bio, Inc. (0002022626) (Filer)

10-K - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug's therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned oper

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global Healthcare Conference, Miami, FLMonday, March 9, 2026, Fireside Chat - 1:40 p.m. ET Live webcasts of the presentations will be available under the Events tab on the Investors section o

8-K - Upstream Bio, Inc. (0002022626) (Filer)